In the right place at the right time: tissue-resident memory T cells in immunity to cancer

Ramirez, Dario C.; Mohamed, Asmaa H.; Huang, Yina H.; Turk, Mary Jo

doi:10.1016/j.coi.2023.102338

Current Opinion in Immunology

2023

DOI: 10.1016/j.coi.2023.102338

|View full text |Cite

In the right place at the right time: tissue-resident memory T cells in immunity to cancer

Dario C. Ramirez

Asmaa H. Mohamed

Yina H. Huang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most CD8 + effector memory cells re‐expressing CD45RA T (Temra/Teff) cells (C8) were from patient 5 (P05), and CD8 + effector memory T (Tem) cells (C7) were mostly from patient 8 (P08); the remaining 10 patients exhibited high heterogeneity in 11 T‐cell sub‐clusters (Supplementary Figure S1E‐F ). Importantly, CD8 + tissue‐resident memory (Trm) cells (C7), which were reported to be associated with forming a tertiary lymphoid structure (TLS) [ 9 ], were less abundant in SD patients (P03, P08, P09, P11, and P12). We also observed that all sub‐clusters expressed ferritin light chain (FTL) (Supplementary Figure S1G ), which was reported to regulate chemoresistance and metastasis in CRC [ 10 ].…”

mentioning

confidence: 99%

Single‐cell landscape of malignant ascites from patients with metastatic colorectal cancer

Zhou,

Yin,

Wang

et al. 2024

Cancer Communications

View full text Add to dashboard Cite

The presence of malignant ascites in colorectal cancer (CRC) patients is associated with a poor prognosis, a high risk of recurrence, and resistance to chemotherapy and immune therapy [1][2][3]. Understanding the complex interactions among different kinds of cells and the ecosystem of peritoneal metastasized colorectal cancer (pmCRC) ascites may provide insights into effective treatment strategies.We profiled the single-cell transcriptomes of 96,065 cells from ascites samples of 12 treatment-naïve patients with pmCRC using the 10× single-cell RNA-sequencing (scRNA-seq) (Supplementary Figure S1A, Supplementary Table S1). Eleven major cell types were identified by characteristic canonical cell markers, including epithelial cells, endothelial cells, fibroblasts, T cells, B cells, monocytes, macrophages, plasma cells, natural killer (NK) cells, dendritic cells (DCs), and mast cells (Figure 1A-B). The main cellular components of pmCRC ascites are T cells (40,095; 41.7%), macrophages (28,487; 29.7%), and fibroblasts (5,932; 6.2%). Compared with primary CRC, which showed 14.8% epithelial cells [4], only 0.3% (291) epithelial cells were found in the ascites. The low percentage of epithelial cells in pmCRC ascites was consistent with the scRNA-seq studies of another tumor ascites [5][6][7].We classified the 12 patients into 2 groups according to their treatment response as follows: 8 patients (P02, P03, P04, P07, P08, P09, P11, and P12) had stable disease (SD), while 4 (P01, P05, P06, and P10) had progressive disease (PD). Single-cell transcriptomic analyses have revealed high heterogeneity of cell composition in 12 patients. The SD group exhibited a higher proportion of fibroblasts and epithelial cells (Figure 1B). Remarkably, fibroblasts had significantly different expression characteristics between the 2 groups (Figure 1C), and the top five upregulated/downregulated genes were visualized in 11 cell types (Figure 1D). We also found a significant increase in the frequency of macrophages in pmCRC ascites compared with the primary tumors [4] (Figure 1E). It hinted that significant inter-patient variability in theThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

show abstract

mentioning

confidence: 99%

Single‐cell landscape of malignant ascites from patients with metastatic colorectal cancer

Zhou,

Yin,

Wang

et al. 2024

Cancer Communications

View full text Add to dashboard Cite

show abstract

MAdCAM-1 co-stimulation combined with retinoic acid and TGF-β induces blood CD8+ T cells to adopt a gut CD101+ TRM phenotype

Girard,

Vimonpatranon,

Chan

et al. 2024

Mucosal Immunology

View full text Add to dashboard Cite

Immune checkpoint blockade: timing is everything

Sinicrope,

Turk

2024

J Immunother Cancer

View full text Add to dashboard Cite

Neoadjuvant immunotherapy effectively uses the in situ tumor as a reservoir of tumor antigens to promote systemic antitumor immunity. Studies indicate that intratumoral responses to immune checkpoint inhibitors (ICIs) are mediated by resident memory T cells cells that are sequestered in tumors and have specificity for a wide range oftumor antigens. ICI treatment produces de novo priming of CD8+T cells in tumor and in tumor-draining lymph nodes, and can boost the antitumor immune response by blocking inhibitory checkpoint proteins that can turn off T cells within the tumor. Neoadjuvant ICI treatment can enhance both intratumoral and systemic antitumor immunity, including expansion of intratumoral T-cell clones which is strongly associated with pathological treatment response. Recent data have shown high rates of pathological response to neoadjuvant immunotherapy with prolongation of survival compared with adjuvant ICI therapy alone in patients with unresectable or advanced melanoma. These data suggest that removal of the reservoir of tumor-specific T cells in the tumor and draining nodes by surgical resection may remove a significant proportion of the patient’s antitumor immunity with the potential to compromise ICI outcomes.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

In the right place at the right time: tissue-resident memory T cells in immunity to cancer

Cited by 3 publications

References 53 publications

Single‐cell landscape of malignant ascites from patients with metastatic colorectal cancer

Single‐cell landscape of malignant ascites from patients with metastatic colorectal cancer

MAdCAM-1 co-stimulation combined with retinoic acid and TGF-β induces blood CD8+ T cells to adopt a gut CD101+ TRM phenotype

Immune checkpoint blockade: timing is everything

Contact Info

Product

Resources

About